A lot of the evidence supporting cannabis’ staggering health benefits is anecdotal (and widely so) - but that is beginning to change. After Canada’s Tilray, a global leader in high quality cannabis distribution for both patients and research, went public in June 2018, their stock has risen 1000% - and the company itself has tripled in value in September alone. On September 18th, 2018, Tilray received approval from the U.S. Government to import medical cannabis for a clinical trial at the University of California San Diego Center for Medical Cannabis Research, specifically for its effects on Essential Tremor (ET). Essential Tremor is classified as a common (more than 200,000 cases per year) nervous system disorder that causes rhythmic shaking in the body, mostly in the hands, voice, arms, tongue, and chin.
Back in 2011, a study revealed:
1) Essential Tremor co-occurs frequently with both Parkinson’s Disease and Alzheimer’s Disease (the two most common neurodegenerative disorders).
2) In the instances where Essential Tremor co-occurs with Parkinson’s or Alzheimer’s, Essential Tremor is always diagnosed first.
Now in 2018, studies like this one and compounding anecdotal health benefits of cannabis have forged the pathway towards new found attitude changes on and interest in the cannabis plant.
The results of this clinical trial for Essential Tremor are anticipated to touch on two important areas:
1) they can provide a new and potentially better treatment option for those afflicted with Essential Tremor and
2) this study can also provide new, reliable information on Essential Tremor itself and how it affects and progresses in the body.
This evidence-based clinical trial could also deliver insights on other common neurodegenerative diseases and comorbid disorders as Essential Tremor is clearly not as benign as once thought. Our new understanding could lead to another drug like “Epidiolex” - a cannabidiol (CBD) oral solution that has been FDA approved in all 50 states for the treatment of severe forms of epilepsy, and the only FDA approved medication for a specific type of epilepsy.
Back in 2011, a study revealed:
1) Essential Tremor co-occurs frequently with both Parkinson’s Disease and Alzheimer’s Disease (the two most common neurodegenerative disorders).
2) In the instances where Essential Tremor co-occurs with Parkinson’s or Alzheimer’s, Essential Tremor is always diagnosed first.
Now in 2018, studies like this one and compounding anecdotal health benefits of cannabis have forged the pathway towards new found attitude changes on and interest in the cannabis plant.
The results of this clinical trial for Essential Tremor are anticipated to touch on two important areas: 1) they can provide a new and potentially better treatment option for those afflicted with Essential Tremor and 2) this study can also provide new, reliable information on Essential Tremor itself and how it affects and progresses in the body.
This evidence-based clinical trial could also deliver insights on other common neurodegenerative diseases and comorbid disorders as Essential Tremor is clearly not as benign as once thought. Our new understanding could lead to another drug like “Epidiolex” - a cannabidiol (CBD) oral solution that has been FDA approved in all 50 states for the treatment of severe forms of epilepsy, and the only FDA approved medication for a specific type of epilepsy.